These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells. Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454 [No Abstract] [Full Text] [Related]
7. Primary immunodeficiencies: molecular aspects and treatment. Fischer A Bone Marrow Transplant; 1992; 9 Suppl 1():39-43. PubMed ID: 1354525 [No Abstract] [Full Text] [Related]
8. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446 [TBL] [Abstract][Full Text] [Related]
9. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Silver JN; Flotte TR Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of gene therapy for SCID is being confirmed. Cavazzana-Calvo M; Fischer A Lancet; 2004 Dec 18-31; 364(9452):2155-6. PubMed ID: 15610783 [No Abstract] [Full Text] [Related]
11. [Gene therapy of primary immunodeficiencies. Present and future]. Serrano F; Laín de Lera T; González MA; García MJ; Abad JL; Bernad A Sangre (Barc); 1999 Apr; 44(2):143-53. PubMed ID: 10382324 [No Abstract] [Full Text] [Related]
12. Gene therapy of primary immunodeficiencies. Fischer A; De Saint Basile G; Disanto JP; Hacein-Bey S; Sharara L; Cavazzana-Calvo M Adv Nephrol Necker Hosp; 1997; 26():107-20. PubMed ID: 8922128 [No Abstract] [Full Text] [Related]
13. Gene therapy for adenosine deaminase deficiency. Cappelli B; Aiuti A Immunol Allergy Clin North Am; 2010 May; 30(2):249-60. PubMed ID: 20493400 [TBL] [Abstract][Full Text] [Related]
14. Genetic manipulation of hematopoietic stem cells in adenosine deaminase deficiency. Williams DA; Moritz T Adv Exp Med Biol; 1994; 370():395-400. PubMed ID: 7660937 [No Abstract] [Full Text] [Related]
16. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases. Candotti F Int J Hematol; 2014 Apr; 99(4):383-92. PubMed ID: 24488786 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of ADA gene expression and transduction efficiency in ADA/SCID patients undergoing gene therapy. Carlucci F; Tabucchi A; Aiuti A; Rosi F; Floccari F; Pagani R; Marinello E Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1245-8. PubMed ID: 15571238 [TBL] [Abstract][Full Text] [Related]
19. Bone marrow transplantation in a case of severe combined immunodeficiency with adenosine deaminase deficiency [proceedings]. Souillet G; Cret L; Freycon F; Dischino M; Touraine JL; Chataing B; Betuel H; Manel AM; Jeune M Pathol Biol (Paris); 1978 Jan; 26(1):30-1. PubMed ID: 29271 [No Abstract] [Full Text] [Related]
20. Genetic therapy using bone marrow transplantation. Giles RE; Hanania EG; Fu S; Deisseroth A Cancer Treat Res; 1995; 76():271-80. PubMed ID: 7577339 [No Abstract] [Full Text] [Related] [Next] [New Search]